Lesson 12 - Long-term Follow-up
1. Introduction
Starting ADHD medication and completing titration are important milestones, but they are not the end of ADHD treatment. For many patients, ADHD is a lifelong condition, and medication may remain part of their treatment for many years. Good prescribing therefore requires clinicians to think beyond the initial response to medication and consider how treatment should be reviewed, monitored and adapted over time.
Long-term follow-up is about ensuring that treatment continues to provide meaningful benefit while remaining safe and appropriate. A medication that worked well during titration should not simply be continued indefinitely without review. Symptoms and functional demands change, children grow and develop, adults move through different stages of life, physical health can change, and adverse effects or problems with adherence may emerge gradually. Regular review provides an opportunity to reconsider both the benefits and burdens of treatment.
Importantly, long-term ADHD follow-up is more than checking blood pressure, pulse and weight before issuing another prescription. A high-quality review considers whether medication is still helping the difficulties for which it was originally prescribed. This means revisiting ADHD symptoms, functional impairment, education or occupational functioning, relationships, emotional wellbeing, sleep, appetite, adverse effects, adherence and the patient's own experience of treatment. It should also consider whether the current dose, preparation and pattern of medication use still fit the patient's life.
Long-term follow-up also requires clinicians to recognise when apparently stable treatment deserves closer attention. Loss of efficacy, increasing adverse effects, cardiovascular concerns, changes in mental state, substance misuse, poor adherence, repeated requests for early prescriptions or unexpected changes in medication use may all require further assessment rather than routine continuation of prescribing.
For children and young people, follow-up has additional importance because treatment takes place against a background of growth, physical development and changing educational and social demands. The balance between benefit and adverse effects may change as a child grows, and medication that was appropriate at one stage of development may require adjustment later. The transition from child to adult services also needs active planning rather than being treated as an administrative event.
For adults, changing employment, relationships, parenthood, physical health and other medication can similarly alter treatment needs. Some patients may require treatment continuously, while others may wish to explore dose reduction, planned periods without medication or stopping treatment altogether. These decisions should be individualised and based on a careful assessment of ongoing benefits, risks and functional needs.
This lesson builds directly on the preceding teaching on medication initiation, titration, monitoring and management of adverse effects. The focus now moves from establishing an effective treatment to maintaining safe, effective and proportionate care over months and years. Learners will consider what should happen during a long-term ADHD medication review, how frequently patients should be reviewed, when monitoring findings require action, how to recognise when treatment needs to change, and how shared-care arrangements can support continuity without removing the specialist prescriber's responsibility for appropriate review.
The aim is to develop an approach in which long-term prescribing is active rather than passive: every review should answer a fundamental clinical question — does this patient continue to benefit sufficiently from this treatment for it to remain the right treatment for them?
2. Learning Outcomes
By the end of this lesson, learners should be able to:
Explain the principles of long-term ADHD management, including the importance of regular clinical review, ongoing assessment of treatment effectiveness and individualised decisions about continuing medication.
Conduct a comprehensive long-term ADHD medication review, evaluating symptom control, functional improvement, adherence, adverse effects, emotional wellbeing, sleep, appetite and the patient's experience of treatment.
Apply recommended monitoring and follow-up schedules in accordance with NICE guidance, including appropriate monitoring of cardiovascular health, weight, height and other relevant clinical parameters, and recognising when more frequent review is necessary.
Recognise when established treatment requires reassessment or adjustment, including reduced effectiveness, emerging adverse effects, changes in physical or mental health, developmental transitions and concerns about medication misuse or diversion.
Evaluate the ongoing need for ADHD medication, using shared decision-making to consider continued treatment, dose adjustments, planned medication breaks or discontinuation where clinically appropriate.
Manage continuity of care and shared-care arrangements safely, understanding the responsibilities of specialist and primary care prescribers, the importance of effective communication, and the need for appropriate specialist review throughout long-term treatment.
3. The Lecture
Long-term Follow-up in ADHD: Maintaining Safe and Effective Treatment
3.1. From Titration to Long-term Management
When we initiate ADHD medication, our immediate objective is relatively straightforward: identify a medication and dose that provide meaningful improvement in symptoms and functioning without causing unacceptable adverse effects.
During titration, patients are usually reviewed frequently. We assess their response, adjust the dose, monitor physical observations and establish whether the medication is helping. Once a patient reaches a stable and effective dose, however, the nature of our clinical responsibility changes.
We are no longer simply asking whether the medication works. We are asking whether it continues to work, whether it remains safe, and whether it is still the most appropriate treatment for that individual.
This distinction is fundamental to good long-term ADHD prescribing.
ADHD is a neurodevelopmental condition, but its clinical presentation and impact are not static. Symptoms may change over time, environmental demands fluctuate, and patients develop new coping strategies. The medication that was appropriate during childhood may not be optimal during adolescence, and a treatment that worked well for an adult in one employment situation may need reconsideration following a significant change in circumstances.
Long-term follow-up therefore needs to be an active process of reassessment rather than the routine renewal of prescriptions.
The central principle is that clinical stability should never be confused with the absence of a need for clinical review.
A patient who has remained on the same medication for several years may be receiving excellent treatment. Equally, they may be experiencing difficulties that have simply never been explored.
Our role is to establish which of these situations applies.
3.2. How Frequently Should Patients Be Reviewed?
One of the first questions newly qualified prescribers ask is how frequently patients taking ADHD medication should be seen once titration has been completed.
The answer depends on the patient's age, clinical circumstances, treatment stability and any emerging concerns.
NICE Recommendations
NICE guideline NG87 recommends that a healthcare professional with training and expertise in managing ADHD should review ADHD medication at least once a year.
This annual review should include a comprehensive assessment of the medication's ongoing benefits, adverse effects, clinical need and the patient's preferences.
However, it is important to distinguish between the minimum frequency of a comprehensive medication review and the frequency of other clinical monitoring.
For example, NICE recommends that heart rate and blood pressure should be monitored before and after each dose change and every six months during ongoing treatment.
Height, weight and growth monitoring have separate recommendations, particularly for children and young people.
Consequently, an annual medication review does not mean that a patient necessarily requires clinical contact only once every twelve months.
A Practical Follow-up Schedule
In clinical practice, a reasonable approach is to arrange follow-up according to the patient's clinical needs.
For many adults whose medication is stable and well tolerated, a six-monthly medication review provides an opportunity to reassess effectiveness, adverse effects and physical health while maintaining continuity of care.
For children and young people, follow-up may need to be more frequent, particularly where growth, appetite, emotional wellbeing or educational functioning require closer attention.
Younger children may benefit from reviews approximately every three months, while older children and adolescents with established treatment may be suitable for six-monthly reviews, depending on clinical circumstances.
These intervals represent a practical service approach rather than a universal NICE requirement. Some patients will need considerably more frequent assessment.
For example, a patient experiencing weight loss, emerging anxiety, cardiovascular symptoms or deteriorating mental health should not be asked to wait until their next routine appointment.
Similarly, a patient whose medication has recently been adjusted may require a return to more frequent monitoring until the treatment is stable again.
The frequency of follow-up should reflect clinical risk and treatment complexity, not simply the amount of time that has passed since titration.
3.3. What Should Happen During a Long-term ADHD Review?
A comprehensive medication review should be structured enough to ensure that important areas are not overlooked, but flexible enough to explore the patient's individual circumstances.
The aim is not to repeat the original diagnostic assessment at every appointment.
Instead, we should focus on whether the current treatment remains effective, safe and appropriate.
Reviewing ADHD Symptoms
The first area to explore is whether the medication continues to provide meaningful improvement in ADHD symptoms.
We should consider the core symptom domains:
Inattention.
Hyperactivity.
Impulsivity.
However, simply asking whether these symptoms have improved is insufficient.
Patients may have difficulty identifying changes in their symptoms, particularly when they have been taking medication for several years.
A more useful approach is to ask about specific situations.
For example, an adult might be asked whether they can still organise their working day, complete tasks, manage appointments and maintain concentration during meetings.
For a child, we might explore classroom engagement, ability to follow instructions, completion of schoolwork, impulsive behaviour and functioning at home.
The key is to establish whether the improvements achieved during titration have been maintained.
Where appropriate, validated ADHD rating scales and collateral information from family members, partners or educational settings can support the clinical assessment.
Nevertheless, rating scales should complement rather than replace clinical judgement.
A patient may have relatively modest changes in questionnaire scores but experience substantial improvements in their everyday functioning.
Reviewing Functional Outcomes
Functional improvement is arguably one of the most important measures of successful ADHD treatment.
Medication is not prescribed simply to reduce the number of ADHD symptoms recorded during an assessment. It is prescribed to improve the patient's ability to function and participate in everyday life.
For children, this might include improved engagement with education, fewer difficulties with peer relationships, greater independence and reduced conflict at home.
For adults, relevant outcomes might include improved occupational functioning, more consistent organisation, safer driving, better management of finances and improved relationships.
Consider an adult who reports that their concentration remains improved but who is increasingly struggling with work.
It would be easy to conclude that their medication is becoming less effective.
However, further discussion might reveal that they have recently been promoted into a management role requiring substantially greater organisational skills.
The medication may still be working as effectively as before, but the demands placed upon the patient have increased.
In this situation, increasing the medication dose may not be the most appropriate intervention. Workplace adjustments, coaching, psychological strategies or changes to organisational systems may be more helpful.
This illustrates why treatment effectiveness must always be interpreted within the patient's current circumstances.
3.4. Assessing the Duration and Consistency of Medication Benefit
An important part of long-term follow-up is establishing whether the medication continues to provide adequate symptom coverage throughout the periods when it is needed.
Patients sometimes describe their medication as having stopped working when the underlying problem is actually related to its duration of action.
For example, a young person taking a modified-release stimulant may function well throughout the school day but experience significant difficulties with homework and emotional regulation during the evening.
This does not necessarily indicate that the medication is ineffective.
It may indicate that the therapeutic effect is wearing off before the patient's daily demands have ended.
Similarly, an adult may experience good concentration during the morning but notice increasing distractibility and impulsivity during the afternoon.
When reviewing these situations, it is useful to explore when the medication is taken, when the patient notices its effects, when benefits diminish and whether there is a predictable pattern of symptom recurrence.
We should also consider whether medication is being taken consistently and whether changes in routine, sleep, food intake or other factors are influencing the patient's experience.
Where clinically appropriate, possible interventions include adjusting administration times, changing formulation or considering an additional short-acting dose.
However, these decisions should take account of the specific preparation, licensed dosing recommendations, maximum recommended doses, adverse effects and the patient's overall clinical circumstances.
A change in symptom coverage should prompt a careful review rather than an automatic dose increase.
3.5. Physical Health Monitoring
Physical monitoring remains an essential part of long-term ADHD prescribing.
Although ADHD medications are generally well tolerated when appropriately prescribed and monitored, they can influence cardiovascular parameters, appetite, weight and growth.
These effects may be apparent during titration, but they can also become clinically significant during longer-term treatment.
Blood Pressure and Heart Rate
NICE recommends measuring heart rate and blood pressure before and after each dose change and every six months during ongoing treatment.
Measurements should be interpreted in the context of the patient's age, physical health, baseline observations and relevant clinical history.
For children and young people, blood pressure should be compared with appropriate age- and height-related reference ranges.
A small increase in heart rate or blood pressure may not require immediate treatment cessation, but persistent or clinically significant abnormalities require further assessment.
NICE recommends reducing the medication dose and referring to an appropriate specialist if a patient taking ADHD medication develops sustained resting tachycardia above 120 beats per minute, an arrhythmia or systolic blood pressure above the 95th percentile, or a clinically significant increase, measured on two occasions.
For adults, referral is to an adult physician; for children and young people, to a paediatric hypertension specialist.
In practice, clinicians should also consider the patient's symptoms and the possibility of underlying cardiovascular disease.
Chest pain, syncope, significant palpitations or other concerning cardiovascular symptoms require prompt clinical assessment.
Where symptoms suggest a potentially serious cardiac problem, stimulant medication should be withheld pending appropriate medical evaluation, and urgent or emergency assessment arranged according to the clinical presentation.
Routine ECGs are not recommended by NICE for patients taking ADHD medication unless there is a clinical indication.
Similarly, routine blood tests are not required solely because a patient is taking ADHD medication, although investigations may be indicated by other medical conditions, symptoms or concurrent treatments.
Weight Monitoring
Weight should be monitored regularly because reduced appetite and weight loss are recognised adverse effects of stimulant medication.
NICE recommends measuring weight every six months in adults.
For children and young people, the recommended schedule is more detailed:
Children aged 10 years and under should have their weight measured every three months.
Children over 10 years should have their weight measured at three and six months after starting medication and every six months thereafter, or more often if concerns arise.
Weight should be plotted on an appropriate growth chart for children and young people.
A single weight measurement provides limited information. The pattern over time is often more clinically useful.
For example, a child may remain within a healthy weight range but show a progressive decline across growth centiles.
This may indicate that medication-related appetite suppression is affecting expected growth and nutritional intake.
Conversely, a child who is naturally small but continues to grow consistently along their established centile may not be experiencing clinically significant medication-related weight loss.
When weight loss becomes concerning, NICE suggests considering strategies such as taking medication with or after food, providing additional meals or snacks when stimulant effects have worn off, obtaining dietary advice, introducing a planned treatment break or changing medication.
The appropriate intervention depends on the severity of the problem and the overall balance of treatment benefits and risks.
Height and Growth
For children and young people, height should be measured every six months.
Measurements should be plotted on a growth chart and interpreted longitudinally.
Growth monitoring is particularly important because stimulant medication may be associated with reduced growth velocity in some children.
This effect is variable, and its longer-term significance differs between individuals.
A clinician should not assume that every change in growth trajectory is caused by medication. Other medical, nutritional and developmental factors may need consideration.
However, where growth is substantially below expectations, the possible contribution of medication should be explored.
NICE recommends considering a planned break from medication over school holidays to allow catch-up growth when a child's height is significantly affected.
This should be an individualised clinical decision, taking account of the benefits of treatment, the child's functioning outside school and the potential consequences of stopping medication.
3.6. Reviewing Adverse Effects Over Time
An adverse effect that was tolerable during titration may become more problematic during long-term treatment.
For example, a patient may initially accept a reduction in appetite because the improvement in concentration is substantial.
Several months later, however, persistent appetite suppression may have resulted in significant weight loss or difficulties maintaining adequate nutrition.
Similarly, a patient may initially experience mild sleep disturbance but later develop persistent fatigue and deteriorating daytime functioning.
Long-term reviews should therefore revisit adverse effects even when the patient has not spontaneously raised concerns.
Important areas include appetite, weight, sleep, headaches, gastrointestinal symptoms, mood changes, irritability, anxiety, tics and cardiovascular symptoms.
We should also consider whether the patient experiences emotional blunting or feels that medication has altered their personality or spontaneity.
Some patients describe feeling excessively quiet, subdued or less emotionally responsive while taking medication.
These experiences deserve careful exploration.
The objective of ADHD treatment is not to suppress the patient's personality or make them easier for other people to manage.
It is to reduce impairing symptoms while preserving wellbeing, autonomy and quality of life.
Where adverse effects are significant, options may include adjusting the dose, changing administration time, changing formulation, switching medication or reconsidering the overall treatment plan.
3.7. Reviewing Mental Health and Comorbid Conditions
ADHD frequently coexists with other mental health and neurodevelopmental conditions.
Anxiety disorders, depression, autism, tic disorders, substance misuse and sleep disorders may all influence the patient's presentation and response to treatment.
Long-term follow-up should therefore include a broader assessment of mental wellbeing rather than focusing exclusively on ADHD symptoms.
Consider a patient who has taken methylphenidate successfully for several years but begins reporting reduced concentration, poor motivation and difficulty completing tasks.
One explanation might be reduced medication effectiveness.
However, further assessment may reveal low mood, loss of interest, early morning waking and feelings of hopelessness.
In this situation, depressive illness may be contributing substantially to the apparent deterioration in ADHD symptoms.
Increasing stimulant medication without recognising the depression could delay appropriate treatment.
Similarly, emerging anxiety may cause restlessness and poor concentration that resemble inadequately treated ADHD.
Clinicians should consider whether symptoms represent ADHD, another condition, an adverse medication effect or a combination of these factors.
Changes in mental state that raise concerns about mania, psychosis or significant risk require particularly careful assessment.
NICE recommends stopping ADHD medication during an acute psychotic or manic episode and considering restarting or introducing medication only after the episode has resolved, following an assessment of individual risks and benefits.
The broader principle is that ADHD medication should never be managed in isolation from the patient's overall psychiatric presentation.
3.8. Adherence and Medication-taking Behaviour
Medication adherence is an important but sometimes overlooked aspect of long-term ADHD management.
Patients may not take medication exactly as prescribed for a variety of reasons.
These include forgetfulness, inconsistent routines, adverse effects, concerns about dependence, medication costs, difficulty obtaining prescriptions and personal preferences about treatment.
ADHD itself can make consistent medication-taking difficult.
An adult with significant executive functioning difficulties may repeatedly forget to request prescriptions or collect medication.
This should not automatically be interpreted as a lack of motivation or engagement.
A supportive approach involves exploring practical barriers and identifying ways to simplify treatment.
For example, a once-daily preparation may be easier to manage than multiple daily doses.
Reminder systems, repeat prescription arrangements and predictable review schedules may also help.
At the same time, clinicians need to remain alert to patterns suggesting medication misuse or diversion.
Repeated reports of lost prescriptions, unusually early requests for medication, unexplained dose escalation or inconsistent accounts of medication use may warrant further assessment.
These findings should prompt a proportionate, non-judgemental exploration of what is happening rather than an immediate assumption of misuse.
Where concerns are identified, the prescribing plan may need to be modified, with additional safeguards and closer monitoring.
3.9. Tolerance and Perceived Loss of Effectiveness
Patients sometimes report that medication which previously worked well has become less effective.
This is frequently described as medication tolerance.
Pharmacological tolerance may occur, but it should not be assumed to be the explanation for every perceived reduction in benefit.
Other possibilities include increasing environmental demands, insufficient sleep, deteriorating mental health, changes in medication adherence, inconsistent administration, interactions with other medication or changes in the patient's expectations.
Before increasing the dose, the clinician should establish what has changed.
For example, a university student may report that their medication no longer helps them concentrate.
Further discussion might reveal that they are sleeping only five hours a night while preparing for examinations.
In this situation, sleep deprivation may be substantially contributing to their difficulties.
Increasing stimulant medication could worsen sleep and potentially exacerbate the problem.
A careful review should therefore consider the timing of symptoms, sleep, mental health, adherence, daily routine and objective evidence of functional change.
Dose increases should be based on a clear clinical rationale and accompanied by appropriate monitoring.
A perceived reduction in medication benefit is a reason to reassess treatment, not automatically a reason to prescribe more medication.
3.10. The Annual Comprehensive Medication Review
Although some aspects of monitoring take place throughout the year, NICE specifically recommends a comprehensive medication review at least annually.
This review should be undertaken by a healthcare professional with training and expertise in managing ADHD.
The annual review provides an opportunity to reconsider the entire treatment plan.
Reviewing Benefits
The clinician should assess how well medication continues to work throughout the day and whether the patient is experiencing meaningful improvements in symptoms and functioning.
The review should also consider whether the patient's needs have changed since treatment was initiated.
Reviewing Adverse Effects
The nature, severity and impact of adverse effects should be explored.
Patients should be encouraged to discuss difficulties even when they believe these are relatively minor.
An adverse effect that appears insignificant to a clinician may be particularly troublesome to the individual experiencing it.
Reviewing the Impact of Missed Doses
The clinician should explore what happens when medication is missed, reduced or not taken.
Some patients notice an immediate deterioration in concentration or impulse control.
Others may report relatively little difference.
These observations can be informative, although they should be interpreted cautiously because expectations, environmental demands and other factors may influence the experience.
Reviewing the Patient's Preferences
Patients should be asked whether they wish to continue medication and whether they have concerns about long-term treatment.
Some may be satisfied with their current regimen.
Others may wish to reduce their dose, explore alternative preparations or consider stopping medication.
These preferences should form part of shared decision-making.
Considering Non-pharmacological Support
Medication should not be viewed as the only intervention available.
Psychological strategies, educational adjustments, workplace accommodations, organisational support and family interventions may remain important throughout treatment.
The annual review provides an opportunity to identify unmet needs and consider whether additional support would be beneficial.
3.11. Medication Breaks and Discontinuation
Long-term ADHD treatment does not necessarily mean lifelong medication.
Some patients continue to benefit from medication for many years, while others may eventually choose to reduce or stop treatment.
The decision should be individualised.
Planned Medication Breaks
A planned medication break involves temporarily stopping medication for a defined period to evaluate ongoing need, adverse effects or other treatment considerations.
For children, medication breaks may sometimes be considered where appetite suppression or growth concerns are significant.
For adults, a supervised period without medication may help clarify whether treatment continues to provide meaningful benefit.
However, medication breaks are not automatically appropriate for every patient.
ADHD can affect functioning outside education and employment, including relationships, emotional regulation, driving and personal safety.
For example, a young person whose medication substantially reduces impulsive behaviour may experience significant difficulties during school holidays if treatment is stopped.
The fact that school is closed does not necessarily mean that ADHD symptoms no longer require treatment.
Any medication break should therefore involve discussion of potential benefits and risks, an agreed plan for monitoring and clear guidance about when treatment should be restarted or reviewed.
Medication-specific considerations are also important. Stimulants and non-stimulants differ in their onset and offset of action, and abrupt interruption may not be appropriate for every preparation. Guanfacine, for example, requires gradual dose reduction because of the risk of increases in blood pressure and pulse following abrupt cessation.
Discontinuing Medication
Patients may wish to stop medication because they no longer perceive sufficient benefit, experience adverse effects or prefer to manage their ADHD through other approaches.
The clinician should explore the reasons for this decision and discuss the potential consequences.
A planned reduction or discontinuation may be appropriate where the balance of benefits and burdens no longer favours continued treatment.
The process should include an assessment of current functioning, a medication-specific stopping plan, monitoring arrangements and a discussion of what to do if symptoms or impairment recur.
Patients should not be made to feel that stopping medication represents failure.
Equally, they should not feel pressured to stop effective medication simply because they have been taking it for several years.
The objective is appropriate treatment, not treatment for the shortest or longest possible duration.
3.12. Shared Care and the Responsibilities of Prescribers
Long-term ADHD treatment often involves collaboration between specialist services and primary care.
In the UK, shared-care arrangements may allow a GP to continue prescribing medication once a patient has completed titration and treatment is stable.
However, shared care should not be confused with transferring all clinical responsibility to primary care.
A shared-care agreement should define the responsibilities of each participating clinician.
The specialist service ordinarily remains responsible for providing appropriate specialist review, advice about medication adjustments and support when treatment becomes more complex, in accordance with the agreed protocol.
The GP's responsibilities may include issuing repeat prescriptions, undertaking specified monitoring and identifying concerns requiring specialist input.
Importantly, shared care is voluntary and requires agreement between the parties involved.
A GP is not obliged to accept a shared-care request, and the existence of a specialist recommendation does not automatically create an obligation for primary care to prescribe.
Where shared care is declined, the specialist provider must ensure that the patient has an appropriate plan for ongoing prescribing and monitoring, or arrange a safe transfer of care.
Communication Between Services
Effective communication is essential.
Specialist correspondence should clearly document the medication, dose, formulation, treatment response, relevant physical observations, adverse effects, monitoring requirements and arrangements for specialist review.
It should also explain when primary care should seek further advice.
Consider a patient whose GP identifies persistently elevated blood pressure during routine monitoring.
The GP should have a clear route for contacting the specialist service, and the specialist should be able to advise on whether medication adjustment or further assessment is required.
Poor communication can result in delayed intervention, duplicated work or uncertainty about prescribing responsibility.
Long-term treatment is safest when each clinician understands their role and the patient knows whom to contact when concerns arise.
3.13. Transition from Child to Adult Services
The transition from childhood to adulthood represents an important period in ADHD management.
During adolescence, the patient's clinical needs, educational circumstances, independence and involvement in treatment decisions may change substantially.
A young person who previously relied on parents to organise medication may gradually become responsible for requesting prescriptions, attending appointments and managing their own treatment.
This transition requires preparation.
NICE recommends that young people receiving treatment and care from child services should be reassessed at school-leaving age to establish the need for continuing treatment into adulthood.
Where ongoing treatment is required, transition planning should take place in advance and should normally be completed by 18 years of age.
The process should involve the young person and, where appropriate and with their agreement, their family or carers.
Developing Independence
Clinicians should encourage young people to understand their diagnosis, medication, potential adverse effects and monitoring requirements.
They should also be supported to recognise when treatment is not working as expected and how to seek help.
A useful approach is to gradually increase the young person's involvement in consultations rather than suddenly expecting full independence at the point of transfer.
Avoiding Gaps in Treatment
One of the major risks during transition is an interruption in prescribing.
This may occur because adult services have different referral criteria, waiting times or prescribing arrangements.
A transition plan should therefore identify who will provide medication and clinical review during the transfer period.
Responsibility should not be assumed to have transferred until appropriate arrangements have been confirmed.
3.14. Long-term Follow-up in Adults
Adult ADHD management introduces additional considerations that may become more relevant over time.
Occupational and Lifestyle Changes
Changes in employment can substantially alter the demands placed upon executive functioning.
A patient moving from a structured workplace into self-employment may suddenly need to manage their own schedule, finances and workload.
Similarly, changes in working hours may affect when medication is most useful.
The clinician should consider whether the treatment regimen remains appropriate for the patient's daily routine.
Pregnancy and Family Planning
Pregnancy planning requires individualised discussion of the potential benefits and risks of continuing ADHD medication.
The evidence base varies between medications, and decisions should consider maternal functioning, the risks of untreated ADHD, available safety data and patient preferences.
Where appropriate, specialist advice should be sought before conception or when pregnancy is identified.
A blanket assumption that every patient must stop ADHD medication during pregnancy is not a substitute for an individualised risk–benefit assessment.
Ageing and Physical Health
As patients grow older, new medical conditions and concurrent medications may affect the safety or suitability of ADHD treatment.
Hypertension, cardiovascular disease, changes in renal or hepatic function and interactions with other medication may become increasingly relevant.
Long-term prescribing should therefore take account of changes in physical health rather than relying indefinitely on the assessment completed when treatment was first initiated.
3.15. When Should Routine Follow-up Become an Urgent Review?
Most long-term ADHD reviews involve stable patients who are functioning well.
However, clinicians must recognise situations where routine monitoring is no longer sufficient.
Examples include significant cardiovascular symptoms, severe or rapidly worsening adverse effects, marked weight loss, concerning changes in mental state, suspected medication misuse or diversion, and substantial deterioration in functioning.
The urgency of assessment should reflect the nature and severity of the concern.
A patient reporting mild appetite reduction may be suitable for a planned review and dietary advice.
A patient reporting new chest pain or syncope requires a very different response.
Similarly, a patient experiencing mild anxiety may need a careful medication review, while acute psychosis, mania or significant suicidal risk may require urgent mental health assessment.
It is important that patients know how to obtain advice between scheduled appointments.
A safe long-term prescribing service should have clear arrangements for responding to clinical concerns, reviewing unexpected monitoring results and providing urgent assessment when necessary.
3.16. Clinical Example: A Patient Who Has Been Stable for Three Years
Consider a 28-year-old adult with ADHD who has been taking lisdexamfetamine 50 mg each morning for three years.
They initially experienced substantial improvements in concentration, organisation and occupational functioning.
They attend for a routine six-monthly review and report that the medication is still helpful.
Their blood pressure and pulse are within acceptable limits, and their weight has remained stable.
At first glance, this appears to be a straightforward review.
However, when asked about their daily routine, they explain that the medication seems to wear off by late afternoon and that they have recently been struggling to manage responsibilities at home.
They have also started a new job requiring longer working hours.
Further discussion reveals that their sleep has reduced from approximately eight hours to six hours per night.
How should we approach this?
The first step is to recognise that the patient continues to benefit from medication.
There is no clear evidence that the medication has stopped working.
Instead, several factors may be contributing to their difficulties: increased occupational demands, reduced sleep and the possibility that medication coverage no longer matches their daily schedule.
The appropriate response is not necessarily to increase the dose.
We should first explore sleep, working patterns, the timing of medication effects and the patient's priorities.
Depending on the findings, possible interventions might include sleep-related strategies, adjustments to working arrangements, changes to medication timing or a carefully considered change in formulation or dose.
Any medication adjustment should be accompanied by appropriate monitoring.
This case illustrates a central feature of good long-term follow-up: the clinician must look beyond the prescription and understand the patient's current life.
3.17. Documentation and Clinical Governance
Every long-term ADHD review should produce a clear clinical record.
Documentation should demonstrate that the clinician has considered treatment effectiveness, functional outcomes, adverse effects, adherence, physical monitoring and relevant mental health concerns.
It should also record the patient's preferences and the rationale for continuing or changing treatment.
Where medication is continued, the record should explain why the current treatment remains appropriate.
Where medication is adjusted, the reason for the change and the associated monitoring plan should be documented.
Where a concern has been identified, the record should demonstrate how it has been addressed.
For example, documenting that blood pressure was elevated is insufficient if there is no explanation of whether it was repeated, how it was interpreted or what action was taken.
Good documentation supports continuity of care, clinical accountability and effective communication between professionals.
It also provides evidence that prescribing decisions are based on active clinical assessment rather than automatic prescription renewal.
3.18. The Long-term Prescribing Mindset
The final point I want to emphasise is that long-term ADHD prescribing requires a slightly different mindset from medication initiation.
During titration, clinicians are often focused on achieving improvement.
During long-term follow-up, the focus becomes maintaining improvement while continually reassessing the balance between benefit and risk.
We should remain curious about the patient's experience, even when treatment appears stable.
We should recognise that clinical circumstances change, and we should be prepared to reconsider decisions that were entirely appropriate at an earlier stage.
At the same time, we should avoid unnecessary medication changes simply because a patient has been taking the same treatment for a long period.
Stability can be a positive clinical outcome.
The objective is not to change medication regularly, but to ensure that continued treatment remains justified.
A successful long-term ADHD review should establish three things: that the medication remains beneficial, that it remains acceptably safe, and that the treatment plan continues to reflect the patient's current needs and preferences.
When these principles guide follow-up, long-term prescribing becomes more than a process of issuing repeat prescriptions. It becomes an ongoing therapeutic relationship that supports patients in managing ADHD safely and effectively throughout different stages of their lives.
4. Clinical Perspective
4.1. Clinical Stability Does Not Mean That Treatment No Longer Requires Attention
One of the most common mistakes in long-term ADHD prescribing is assuming that a patient who has remained on the same medication for several years requires very little clinical attention.
In many cases, stability is an excellent outcome. A patient who continues to function well, experiences meaningful benefits and has no significant adverse effects may not require any changes to their treatment.
However, stability should be established through clinical assessment rather than assumed from the absence of complaints.
Patients do not always volunteer information about adverse effects, particularly when they believe these are an unavoidable consequence of taking medication. Some may have experienced reduced appetite, poor sleep or emotional blunting for so long that they regard these as normal.
A useful approach is to ask specific questions rather than relying on a general enquiry about side effects.
For example, instead of simply asking whether medication is causing any problems, explore appetite, sleep, mood, physical symptoms and how the patient feels when taking medication.
Clinical pearl: A stable prescription does not necessarily indicate a stable patient. The purpose of follow-up is to establish whether treatment remains appropriate, not simply whether the patient has requested a change.
4.2. Focus on Functioning Rather Than Symptom Scores Alone
ADHD rating scales can be useful during long-term follow-up, particularly when assessing changes over time.
However, they should never become the sole measure of treatment success.
A patient may continue to score relatively highly on an ADHD questionnaire while experiencing substantial improvements in occupational functioning, relationships and daily organisation.
Conversely, a patient may report fewer ADHD symptoms but experience little meaningful improvement in everyday life.
For example, a parent may describe their child as considerably quieter while taking medication. This might initially sound like a positive treatment response.
However, further discussion may reveal that the child has become withdrawn, less communicative and reluctant to participate in activities they previously enjoyed.
In this situation, reduced activity should not automatically be interpreted as successful treatment of hyperactivity.
We need to distinguish between improved self-regulation and excessive suppression of normal behaviour.
Clinical pearl: The aim of ADHD medication is not to make a patient quieter or more compliant. It is to reduce impairing symptoms while supporting their ability to function, participate and maintain their individuality.
4.3. Do Not Automatically Increase Medication When Effectiveness Appears to Decline
Patients occasionally report that their medication is no longer working as well as it used to.
For an inexperienced prescriber, the temptation may be to increase the dose.
However, apparent loss of effectiveness has several possible explanations.
Sleep deprivation, increased environmental demands, anxiety, depression, inconsistent medication use and changes in daily routine can all affect concentration and executive functioning.
Consider an adult who has been stable on methylphenidate for two years but reports increasing difficulties with concentration.
Further assessment reveals that they have recently become a parent and are sleeping only four or five hours per night.
Increasing stimulant medication may provide little additional benefit and could potentially worsen their sleep.
The more appropriate intervention may involve addressing sleep deprivation and reviewing their daily demands before considering medication adjustments.
When loss of benefit is reported, establish whether the problem involves reduced symptom control, inadequate duration of action or a change in the patient's circumstances.
Clinical pearl: Before increasing the dose of an established ADHD medication, identify what has changed in the patient's life, health or medication-taking behaviour.
4.4. Take Physical Monitoring Seriously, Even When the Patient Feels Well
Physical observations are sometimes treated as an administrative requirement during long-term prescribing.
This is a mistake.
Blood pressure, pulse, weight and growth monitoring provide important information about the ongoing safety of treatment.
A patient may feel entirely well despite developing clinically significant hypertension or progressive weight loss.
For children, changes in growth trajectory may be particularly important because they can develop gradually and may not be apparent from a single measurement.
When reviewing physical observations, compare current measurements with previous results rather than considering them in isolation.
For example, an adult whose blood pressure has increased progressively over several reviews may require further assessment even if a single reading does not appear particularly concerning.
Similarly, a child who remains within a normal weight range may nevertheless be experiencing a significant decline in their expected growth trajectory.
Abnormal findings should prompt appropriate repeat measurement, interpretation and action.
Clinical pearl: Physical monitoring is only useful when the results influence clinical decision-making. Recording an abnormal observation without considering its significance does not constitute adequate monitoring.
4.5. Remember That ADHD Affects Medication Adherence
One of the more frustrating aspects of ADHD prescribing is that the condition being treated can itself interfere with the patient's ability to manage treatment.
Patients may forget appointments, request prescriptions late, lose medication or struggle to maintain a consistent routine.
These difficulties should not automatically be interpreted as irresponsibility or poor motivation.
For some patients, managing medication is itself an executive functioning task requiring planning, organisation and prospective memory.
A supportive prescribing approach may involve simplifying the medication regimen, agreeing predictable review dates and encouraging practical reminder systems.
However, clinicians must also distinguish between difficulties caused by ADHD and patterns that may indicate medication misuse or diversion.
Repeated early prescription requests, unexplained dose escalation or inconsistent accounts of medication use should prompt further assessment.
The key is to remain supportive without abandoning appropriate prescribing safeguards.
Clinical pearl: Good ADHD prescribing requires systems that accommodate executive functioning difficulties while maintaining safe controlled-drug prescribing practices.
4.6. Do Not Assume That Medication Is Only Needed for School or Work
A common misconception is that ADHD medication is primarily required to support academic or occupational performance.
This can lead clinicians to recommend medication breaks during weekends, holidays or periods away from employment without fully considering the consequences.
ADHD affects more than concentration.
Impulsivity, emotional regulation, organisation and executive functioning can influence family relationships, social interactions, driving and personal safety.
For some patients, medication may be particularly valuable outside school or work.
Consider an adolescent whose medication improves emotional regulation and reduces impulsive conflict at home.
Stopping medication every weekend may result in significant difficulties for the young person and their family, even though there are no educational demands during those days.
Medication breaks should therefore be individualised rather than routinely recommended.
Clinical pearl: The decision to continue medication during weekends and holidays should be based on the patient's functional needs, not simply whether they are attending school or work.
4.7. Avoid Making Medication Changes Simply Because Treatment Has Continued for Several Years
Some clinicians become uncomfortable when patients remain on the same medication for prolonged periods.
This can lead to unnecessary dose reductions, medication switches or attempts to stop treatment despite continued benefit.
There is no general requirement to change an effective ADHD medication simply because it has been prescribed for several years.
If the patient continues to experience meaningful improvement, tolerates treatment well and has satisfactory monitoring results, continuing the established regimen may be entirely appropriate.
The annual medication review should include consideration of whether treatment remains necessary, but this does not mean that every patient must undergo a medication break.
A decision to reduce or stop medication should be based on an individualised assessment of benefits, adverse effects, preferences and clinical circumstances.
Clinical pearl: Continuing effective treatment is an active clinical decision when it follows an appropriate review. It should not be confused with passive prescribing.
4.8. Recognise When a Routine Review Needs to Become a More Detailed Assessment
Long-term follow-up appointments are often relatively straightforward, but occasionally a seemingly routine review reveals a significant clinical concern.
For example, a patient may attend requesting their usual prescription but mention that they have recently experienced episodes of chest discomfort and palpitations.
Another patient may describe increasing irritability, reduced sleep and unusually elevated mood.
A third may reveal substantial weight loss that has not previously been recognised.
In these circumstances, the clinician should not feel obliged to complete the appointment as a routine medication review.
The priority becomes assessing the new concern and determining whether continued prescribing is safe.
Potentially serious cardiovascular symptoms require prompt assessment, and stimulant medication should be withheld where a significant cardiac problem is suspected until appropriate evaluation has taken place.
Similarly, emerging mania or psychosis requires urgent clinical consideration. NICE recommends stopping ADHD medication during an acute psychotic or manic episode.
The appropriate response will depend on the severity of the presentation, but the clinician must be prepared to change the purpose of the consultation.
Clinical pearl: The fact that an appointment was booked as a routine follow-up does not mean that the clinical situation is routine.
4.9. Shared Care Does Not Remove the Need for Specialist Oversight
Shared-care arrangements can be valuable in supporting continuity of ADHD treatment.
However, a common misconception is that once a GP has accepted shared care, the specialist service no longer needs to remain involved.
This is not the case.
The specialist service should continue to provide the reviews, advice and oversight specified within the agreed shared-care arrangement.
For example, a patient may remain stable for several years while receiving repeat prescriptions from their GP.
If they subsequently experience reduced effectiveness, significant adverse effects or a change in their clinical circumstances, they may require specialist reassessment.
Clear communication is essential so that both the GP and specialist understand their responsibilities.
Prescribers should also remember that shared care requires agreement. A GP cannot be assumed to have accepted prescribing responsibility simply because a request has been sent.
Where shared care is declined, safe arrangements for ongoing prescribing and monitoring remain necessary.
Clinical pearl: Shared care distributes agreed responsibilities between clinicians; it does not eliminate the need for specialist involvement or transfer responsibility without consent.
4.10. Be Particularly Careful During Developmental Transitions
Long-term ADHD treatment often spans important developmental stages.
A child may begin medication during primary school and continue treatment through adolescence and into adulthood.
During this period, the patient's symptoms, functional demands, physical development and ability to manage their own treatment may change substantially.
A medication regimen that was appropriate at age eight may need reconsideration at age sixteen.
However, developmental changes do not automatically mean that a dose increase is required.
For example, an adolescent may begin experiencing greater organisational difficulties as educational demands increase.
The medication may still be providing meaningful benefit, but the young person may need additional support with planning, independent study and time management.
Transition planning should also address practical issues such as prescription management, appointment attendance and understanding adverse effects.
Clinical pearl: The transition to adult ADHD care should involve the gradual development of independence and self-management skills, not simply a change in the name of the prescribing service.
4.11. Advice for Newly Qualified Prescribers
For clinicians beginning to undertake long-term ADHD reviews, consistency and structure are particularly important.
A practical approach is to ensure that every review addresses five fundamental questions.
First, is the medication still helping?
Explore symptom control and functional improvement using examples from the patient's everyday life.
Second, is the medication still safe and well tolerated?
Review adverse effects, relevant physical observations and any changes in physical or mental health.
Third, is the patient taking medication as intended?
Explore adherence, practical difficulties, treatment preferences and any concerns about medication use.
Fourth, has anything changed since the previous review?
Consider education, employment, relationships, sleep, physical health, mental health and other relevant circumstances.
Finally, what is the appropriate plan going forward?
Decide whether to continue treatment unchanged, adjust medication, arrange additional monitoring, provide other interventions or reconsider the ongoing need for medication.
For newly qualified prescribers, it is also important to recognise the limits of one's competence.
Unexplained cardiovascular abnormalities, significant psychiatric deterioration, complex medication interactions or uncertainty about ongoing prescribing safety should prompt discussion with an experienced colleague or referral to an appropriate specialist.
Seeking advice is a component of safe prescribing, not a sign of inadequate clinical ability.
4.12. The Importance of Shared Decision-making
Long-term ADHD treatment should be a collaborative process.
Patients may have different priorities at different stages of life.
An adolescent may place particular importance on academic performance, while an adult may be more concerned about emotional regulation, relationships or managing responsibilities at home.
Some patients may prioritise maximum symptom reduction, while others may prefer a lower dose that provides slightly less symptom control but fewer adverse effects.
There is not always a single objectively correct medication regimen.
The clinician's responsibility is to explain the available options, assess their safety and support the patient in making an informed decision.
For children and young people, the patient's own views should be explored in a developmentally appropriate way, alongside the involvement of parents or carers where appropriate.
A parent may be pleased that their child is quieter and more organised, while the child may dislike how medication makes them feel.
Both perspectives are clinically relevant.
Clinical pearl: The best long-term ADHD treatment is not necessarily the regimen producing the greatest reduction in symptoms. It is the treatment that offers the most appropriate balance of benefit, tolerability, safety and patient preference.
4.13. A Final Perspective: Long-term Follow-up Is About the Person, Not the Prescription
Perhaps the most important lesson for clinicians is that long-term ADHD management should never become a purely prescription-focused activity.
A patient may remain on the same medication for many years, but their life will not remain unchanged.
They may move between educational settings, begin employment, develop relationships, become parents, experience physical illness or encounter new mental health difficulties.
Each of these changes may influence how ADHD affects their functioning and what they need from treatment.
A good long-term review therefore involves curiosity, clinical judgement and an understanding of the individual beyond their diagnosis.
The clinician should be willing to continue effective treatment when appropriate, reconsider medication when circumstances change and recognise when additional interventions are needed.
Above all, the patient should leave the consultation feeling that their treatment has been meaningfully reviewed rather than simply renewed.
The defining feature of high-quality long-term ADHD prescribing is not how frequently medication is changed, but how thoughtfully the decision to continue or change treatment is made.
5. Summary
Long-term follow-up is an essential component of safe and effective ADHD prescribing. Although successful titration establishes an appropriate medication and dose, ongoing clinical review is necessary to ensure that treatment continues to provide meaningful benefits while remaining safe, tolerable and appropriate to the patient's changing circumstances.
The key learning points from this lesson are:
Long-term ADHD management requires active clinical review. Patients who remain stable on medication should continue to receive regular assessment of treatment effectiveness, adverse effects, physical health and functional outcomes. Clinical stability should not be confused with an absence of need for monitoring.
Follow-up frequency should reflect individual clinical needs. NICE recommends a comprehensive ADHD medication review at least annually, alongside regular physical health monitoring. More frequent reviews may be appropriate for children, patients with complex presentations or those experiencing adverse effects or changes in treatment response.
Treatment effectiveness should be assessed through functional improvement. Reductions in ADHD symptoms are important, but clinicians should also consider education, employment, relationships, emotional wellbeing and everyday functioning. The objective is to improve quality of life rather than simply reduce symptom scores.
Physical health monitoring remains essential throughout treatment. Blood pressure and pulse should be monitored before and after dose changes and every six months during ongoing treatment. Weight should be monitored according to age, and children and young people also require regular height and growth monitoring. Abnormal findings must be interpreted and acted upon appropriately.
Changes in medication effectiveness require careful assessment. Apparent loss of benefit may reflect increased environmental demands, poor sleep, mental health difficulties, inconsistent adherence or inadequate duration of action. Increasing the medication dose should not be the automatic response.
Adverse effects and mental health should be reviewed routinely. Appetite suppression, sleep disturbance, cardiovascular symptoms, emotional changes and emerging psychiatric difficulties may develop or become more significant during long-term treatment. Clinicians must recognise when routine follow-up needs to become a more detailed or urgent assessment.
Medication adherence should be explored sensitively. Executive functioning difficulties can interfere with prescription management and consistent medication use. Prescribers should provide practical support while remaining alert to potential medication misuse or diversion.
The ongoing need for medication should be reconsidered collaboratively. Planned medication breaks, dose reductions or discontinuation may be appropriate for some patients, but should not be imposed routinely. Decisions should reflect the individual's clinical needs, treatment benefits, adverse effects and preferences.
Shared care and transitions require clear clinical responsibility. Shared-care arrangements should define the responsibilities of specialist and primary care prescribers. Transition between child and adult services must be planned carefully to avoid interruptions in treatment and support increasing independence.
Long-term prescribing should remain individualised and patient-centred. ADHD symptoms, functional demands and personal circumstances change throughout life. Effective follow-up requires clinicians to adapt treatment when necessary while avoiding unnecessary changes to medication that remains beneficial and well tolerated.
Key Message
Successful long-term ADHD prescribing is not simply about maintaining a stable dose or issuing repeat prescriptions. It involves continually reassessing whether treatment remains beneficial, safe and appropriate for the individual.
Every long-term review should answer three fundamental questions: Is the medication still helping? Is it still safe? And does the current treatment plan remain appropriate for this patient's needs?
When these questions guide clinical practice, long-term ADHD management becomes a proactive, collaborative and clinically meaningful process that supports patients throughout different stages of their lives.
6. Further Reading
The following resources are recommended to consolidate understanding of long-term ADHD management, medication monitoring, treatment effectiveness, adverse effects and continuity of care.
Particular emphasis should be placed on NICE guideline NG87, which provides the principal framework for ADHD prescribing and monitoring in UK clinical practice. International consensus statements and longitudinal research offer additional perspectives on the benefits, limitations and safety of extended pharmacological treatment.
6.1. NICE Guidance
1. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline NG87.
https://www.nice.org.uk/guidance/ng87
This is the essential reference for clinicians prescribing ADHD medication in the UK.
Learners should pay particular attention to the recommendations covering:
Maintenance and monitoring of ADHD medication.
Monitoring of blood pressure, pulse, weight and growth.
Recognition and management of adverse effects.
Annual medication reviews.
Consideration of medication reduction and discontinuation.
Shared treatment planning and transition between services.
Clinical relevance: NG87 establishes the minimum standards expected in routine ADHD medication monitoring and provides a framework for deciding when further assessment or treatment adjustment is necessary.
6.2. National and International Clinical Guidelines
2. Australian ADHD Professionals Association (AADPA). Australian Evidence-Based Clinical Practice Guideline for ADHD. 2022.
https://adhdguideline.aadpa.com.au/
This comprehensive guideline addresses ADHD across the lifespan, including pharmacological treatment, ongoing monitoring, treatment adherence and shared decision-making.
It is particularly useful for understanding how long-term treatment decisions should be individualised according to changing symptoms, functional impairment, adverse effects and patient preferences.
Clinical relevance: Provides an international perspective on continuing treatment, monitoring clinical outcomes and supporting patients through different developmental stages.
3. Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines.
The CADDRA guidelines provide practical recommendations for ADHD assessment and management across childhood, adolescence and adulthood.
They include useful approaches to medication selection, treatment optimisation, monitoring and follow-up.
Clinical relevance: Particularly helpful for clinicians developing structured approaches to routine medication reviews and evaluating treatment effectiveness in everyday practice.
4. Wolraich ML, Hagan JF, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4).
https://doi.org/10.1542/peds.2019-2528
This American Academy of Pediatrics guideline emphasises ADHD as a chronic condition requiring coordinated, longitudinal care.
It highlights the importance of monitoring functional outcomes, treatment effectiveness, adverse effects and family engagement.
Clinical relevance: Reinforces the importance of treating ADHD as an ongoing clinical condition rather than focusing exclusively on diagnosis and initial medication titration.
6.3. Landmark Research Papers
5. MTA Cooperative Group. A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.
https://doi.org/10.1001/archpsyc.56.12.1073
The Multimodal Treatment Study of Children with ADHD (MTA) is one of the most influential studies in ADHD treatment research.
It compared carefully managed medication treatment, behavioural interventions, combined treatment and community care.
The findings demonstrated the importance of systematic medication management while also highlighting the value of broader interventions.
Clinical relevance: Provides a foundation for understanding why medication optimisation and structured clinical follow-up are important components of ADHD treatment.
6. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study. Journal of the American Academy of Child & Adolescent Psychiatry. 2009;48(5):484–500.
https://doi.org/10.1097/CHI.0b013e31819c23d0
This longitudinal follow-up of the MTA cohort examined outcomes several years after the original treatment study.
It demonstrated the complexity of long-term ADHD outcomes and the influence of factors beyond the initial treatment approach.
Clinical relevance: Encourages clinicians to avoid assuming that early treatment response automatically predicts long-term functioning. Ongoing assessment of symptoms, impairment and changing clinical needs remains essential.
7. Cortese S, Adamo N, Del Giovane C, et al. Comparative Efficacy and Tolerability of Medications for Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults: A Systematic Review and Network Meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.
https://doi.org/10.1016/S2215-0366(18)30269-4
This major network meta-analysis compared the efficacy and tolerability of medications used to treat ADHD across different age groups.
It provides important evidence supporting medication selection while recognising that treatment effects and tolerability differ between individuals.
Most included trials assessed relatively short-term outcomes, meaning the findings should not be interpreted as definitive evidence about long-term effectiveness.
Clinical relevance: Helps prescribers understand the evidence supporting medication treatment and the importance of balancing clinical benefit against adverse effects.
8. Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(11).
https://doi.org/10.1001/jamanetworkopen.2022.43597
This systematic review and meta-analysis examined associations between ADHD medication use and cardiovascular disease across different age groups.
The findings did not demonstrate a statistically significant association overall, although the confidence intervals did not exclude a modest increase in risk, particularly for some cardiovascular outcomes.
Clinical relevance: Supports a balanced understanding of cardiovascular safety while reinforcing the need for individual risk assessment and appropriate physical monitoring.
6.4. High-quality Reviews and Consensus Statements
9. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions About the Disorder. Neuroscience & Biobehavioral Reviews. 2021;128:789–818.
https://doi.org/10.1016/j.neubiorev.2021.01.022
This international consensus statement summarises a substantial body of evidence concerning ADHD, including its persistence across the lifespan, associated impairment, treatment effectiveness and medication safety.
Clinical relevance: Provides an evidence-based foundation for explaining why some patients require long-term treatment and why management should consider functioning, comorbidities and quality of life.
10. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-Deficit Hyperactivity Disorder. The Lancet. 2020;395(10222):450–462.
https://doi.org/10.1016/S0140-6736(19)33004-1
This comprehensive review explores ADHD epidemiology, neurobiology, clinical presentation and treatment across the lifespan.
It provides a useful overview of ADHD as a developmental condition whose clinical impact can change over time.
Clinical relevance: Helps clinicians place long-term medication management within the broader context of ADHD progression, functional impairment and coexisting psychiatric conditions.
6.5. Additional Prescribing Resources
11. British National Formulary (BNF) and British National Formulary for Children (BNFC).
The BNF and BNFC provide medication-specific information on indications, dosing, contraindications, cautions, interactions and adverse effects.
Prescribers should consult the current relevant monograph when making treatment decisions, particularly when adjusting doses, switching preparations or managing complex clinical presentations.
Clinical relevance: An essential practical reference for safe prescribing and medication-specific decisions during long-term follow-up.
12. Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Updates.
https://www.gov.uk/drug-safety-update
MHRA safety communications provide important information about emerging medication risks, prescribing precautions and changes to safety recommendations.
Clinical relevance: Supports ongoing prescribing competence by helping clinicians remain aware of new safety information that may affect established treatment.
7. Knowledge Check
Long-term Follow-up in ADHD
This formative assessment is designed to consolidate understanding of long-term ADHD medication management, including treatment effectiveness, physical health monitoring, adverse effects, medication adherence, shared care and clinical decision-making.
Each question has one best answer. The explanations explore why the correct option is appropriate and why the alternatives are less suitable.
Question 1. Frequency of Long-term Medication Reviews
A 32-year-old adult with ADHD has been taking lisdexamfetamine 50 mg daily for two years. Their symptoms are well controlled, they report no significant adverse effects, and their physical observations remain satisfactory.
According to NICE guideline NG87, what is the minimum recommended frequency for a comprehensive ADHD medication review by a healthcare professional with training and expertise in managing ADHD?
A. Every three months.
B. Every six months.
C. At least once every twelve months.
D. Only when the patient reports adverse effects.
Correct answer: C. At least once every twelve months.
Explanation:
NICE recommends that ADHD medication should be reviewed at least annually by a healthcare professional with training and expertise in managing ADHD.
The review should consider ongoing treatment effectiveness, functional benefits, adverse effects, clinical need and the patient's preferences.
However, the annual review is a minimum standard for comprehensive medication assessment rather than a recommendation that all patients should have clinical contact only once a year. Blood pressure and pulse monitoring, for example, are recommended every six months during ongoing treatment.
Why the other answers are incorrect:
A: Three-monthly reviews may be appropriate for patients requiring closer supervision, but NICE does not mandate this interval for every stable patient.
B: Six-monthly medication reviews are a reasonable clinical approach and may be adopted by individual services. However, the minimum NICE requirement for a comprehensive medication review is annual.
D: Waiting until adverse effects are reported risks missing changes in treatment effectiveness, physical health and functional outcomes.
Key learning point: Stable ADHD medication requires a comprehensive specialist review at least annually, alongside other monitoring at the recommended intervals.
Question 2. Assessing Long-term Treatment Effectiveness
A 14-year-old young person has been taking modified-release methylphenidate for eighteen months. Their parents report that they are considerably quieter and less disruptive. However, the young person explains that they feel emotionally flat, rarely enjoy spending time with friends and no longer participate in activities they previously enjoyed.
What is the most appropriate clinical response?
A. Continue medication unchanged because reduced hyperactivity indicates successful treatment.
B. Increase the dose to improve the remaining ADHD symptoms.
C. Explore the young person's experience, assess possible adverse effects and mental health difficulties, and reconsider the treatment plan.
D. Advise the parents that emotional changes are an unavoidable consequence of effective ADHD treatment.
Correct answer: C. Explore the young person's experience, assess possible adverse effects and mental health difficulties, and reconsider the treatment plan.
Explanation:
ADHD treatment should improve functioning and quality of life without causing unacceptable adverse effects.
Although reduced hyperactivity may indicate a positive response, emotional blunting, withdrawal and loss of enjoyment may suggest that treatment is adversely affecting the young person's wellbeing. These symptoms could also reflect an emerging mental health condition, such as depression.
The clinician should explore the timing and nature of these changes, assess mental health and consider whether medication adjustments are appropriate.
Why the other answers are incorrect:
A: Reduced activity does not necessarily represent improved self-regulation. Excessive sedation or emotional suppression should not be mistaken for treatment success.
B: Increasing the dose without assessing the reported difficulties could worsen medication-related adverse effects.
D: Emotional blunting is not an inevitable or acceptable consequence of ADHD treatment and should be investigated.
Key learning point: Long-term treatment effectiveness must be assessed through wellbeing and functional improvement, not simply reductions in observable behaviour.
Question 3. Cardiovascular Monitoring
A 25-year-old adult has been taking methylphenidate for six months. They attend a routine follow-up appointment and have no cardiovascular symptoms.
According to NICE guidance, how frequently should heart rate and blood pressure ordinarily be monitored during established ADHD medication treatment?
A. Every month.
B. Every three months.
C. Every six months and before and after each dose change.
D. Only if the patient develops palpitations or chest pain.
Correct answer: C. Every six months and before and after each dose change.
Explanation:
NICE recommends measuring heart rate and blood pressure before and after each dose change and every six months during ongoing ADHD medication treatment.
These observations are important because ADHD medications can affect cardiovascular parameters, sometimes without causing noticeable symptoms.
Results should be interpreted in the context of previous measurements, age, clinical history and associated symptoms.
Why the other answers are incorrect:
A: Monthly monitoring may be necessary in selected circumstances but is not routinely required for every stable patient.
B: Three-monthly monitoring may be clinically appropriate where additional concerns exist, but it is not the standard NICE interval for stable treatment.
D: Cardiovascular abnormalities may occur without symptoms. Monitoring only when symptoms develop is insufficient.
Key learning point: Cardiovascular monitoring is a routine component of long-term ADHD prescribing, even when the patient feels well.
Question 4. Growth and Weight Monitoring
An 8-year-old child has been taking lisdexamfetamine for nine months. Their ADHD symptoms have improved considerably, but their appetite has reduced and their weight gain has slowed.
Which monitoring schedule is recommended by NICE for a child of this age receiving ADHD medication?
A. Weight every six months and height annually.
B. Weight every three months and height every six months.
C. Weight and height every twelve months.
D. Growth monitoring only if the parents report concerns.
Correct answer: B. Weight every three months and height every six months.
Explanation:
NICE recommends that children aged 10 years and under should have their weight measured every three months.
Height should be measured every six months in children and young people.
Measurements should be plotted on appropriate growth charts and interpreted over time.
In this case, reduced appetite and slowing weight gain warrant additional clinical attention. The clinician should review nutritional intake, growth trajectory and the balance between treatment benefit and adverse effects.
Why the other answers are incorrect:
A: Six-monthly weight monitoring is less frequent than the NICE recommendation for children aged 10 years and under, and annual height monitoring is insufficient.
C: Annual measurements would not provide adequate monitoring of growth and weight during treatment.
D: Growth changes may develop gradually and may not be recognised by parents. Routine monitoring is therefore necessary.
Key learning point: Children receiving ADHD medication require age-appropriate growth monitoring, with additional assessment when weight gain or growth becomes concerning.
Question 5. Apparent Loss of Medication Effectiveness
A 35-year-old adult has been taking lisdexamfetamine 40 mg daily for two years with good results.
During a routine review, they explain that their concentration has deteriorated over the previous month and request a higher dose.
Further discussion reveals that they have recently started working longer hours and are sleeping approximately five hours per night.
What is the most appropriate initial response?
A. Increase lisdexamfetamine immediately because the patient has developed tolerance.
B. Switch to another stimulant without further assessment.
C. Explore sleep deprivation, increased occupational demands, medication adherence and other possible explanations before considering a dose adjustment.
D. Stop ADHD medication permanently because it is no longer effective.
Correct answer: C. Explore sleep deprivation, increased occupational demands, medication adherence and other possible explanations before considering a dose adjustment.
Explanation:
A perceived reduction in medication effectiveness does not necessarily indicate pharmacological tolerance.
Sleep deprivation, increased environmental demands, mental health difficulties and inconsistent medication use can all contribute to worsening concentration and executive functioning.
The clinician should establish whether the medication has genuinely become less effective or whether other factors are influencing the patient's functioning.
Addressing sleep and occupational demands may improve symptoms without requiring a medication increase.
Why the other answers are incorrect:
A: Tolerance should not be assumed without considering alternative explanations. Increasing stimulant medication could worsen sleep difficulties.
B: Switching medication prematurely may disrupt an otherwise effective treatment regimen.
D: A short period of deteriorating concentration does not establish that long-term ADHD medication is no longer beneficial.
Key learning point: Apparent loss of effectiveness should trigger reassessment rather than automatic dose escalation.
Question 6. Medication Breaks
A 12-year-old child has been taking modified-release methylphenidate for two years.
Their teacher reports substantial improvements in classroom functioning. However, their parents are concerned about reduced appetite and slowing growth.
The family asks whether the medication should be stopped during the summer holidays.
What is the most appropriate response?
A. Advise that all children taking stimulants must stop medication during school holidays.
B. Explain that medication breaks should never be considered because ADHD is a lifelong condition.
C. Discuss an individualised, planned medication break, considering growth concerns, symptom control outside school, potential risks and arrangements for monitoring.
D. Stop medication immediately and advise the family to restart it whenever they feel it is needed, without further clinical review.
Correct answer: C. Discuss an individualised, planned medication break, considering growth concerns, symptom control outside school, potential risks and arrangements for monitoring.
Explanation:
NICE recommends considering a planned break from medication over school holidays to allow catch-up growth when a child's height is significantly affected by medication.
However, medication breaks should be individualised.
ADHD symptoms can affect relationships, emotional regulation, social functioning and safety outside the school environment.
The clinician should therefore consider the child's needs during the holiday period, the severity of growth concerns, the potential benefits of stopping medication and the risks of symptom recurrence.
A clear plan for monitoring and restarting treatment should be agreed.
Why the other answers are incorrect:
A: Routine medication breaks are not required for every child receiving stimulant treatment.
B: Planned breaks may be appropriate in selected circumstances, particularly where growth is significantly affected.
D: Unplanned stopping and restarting without appropriate guidance may lead to difficulties with symptom control and safe medication management.
Key learning point: Medication breaks should be planned clinical interventions rather than automatic responses to school holidays.
Question 7. Shared-care Responsibilities
A 29-year-old adult with ADHD has completed medication titration and has remained stable on methylphenidate for several months.
The specialist service sends a shared-care request to the patient's GP.
The GP responds that they are unable to accept prescribing responsibility.
What is the most appropriate action?
A. Inform the patient that their GP is legally required to prescribe because the specialist has recommended treatment.
B. Stop issuing prescriptions immediately because the specialist service has completed titration.
C. Ensure that appropriate ongoing prescribing and monitoring arrangements remain in place while discussing available options with the patient.
D. Advise the patient to obtain medication independently until the GP agrees to prescribe.
Correct answer: C. Ensure that appropriate ongoing prescribing and monitoring arrangements remain in place while discussing available options with the patient.
Explanation:
Shared-care prescribing requires agreement between the participating clinicians.
A GP is not obliged to accept a shared-care request.
Where shared care is declined, the specialist service must ensure that prescribing responsibility is not incorrectly assumed to have transferred.
Appropriate arrangements for continued treatment, monitoring or safe transfer of care should be considered.
The patient should receive a clear explanation of their options and the responsibilities of the professionals involved.
Why the other answers are incorrect:
A: Shared care is voluntary and cannot be imposed upon a GP.
B: Completion of titration does not remove the need for ongoing prescribing arrangements.
D: Patients should not be left to obtain prescribed controlled medication independently because of a disagreement about shared care.
Key learning point: A shared-care request does not transfer prescribing responsibility unless the arrangement has been accepted.
Question 8. Recognising Cardiovascular Concerns
A 40-year-old adult has been taking lisdexamfetamine for eighteen months.
During a routine follow-up, they explain that they have recently experienced episodes of chest discomfort associated with palpitations.
They ask whether they can continue taking their medication while waiting for their next routine review.
What is the most appropriate response?
A. Continue medication unchanged because cardiovascular adverse effects usually occur only during titration.
B. Increase the dose because anxiety may be contributing to the symptoms.
C. Withhold stimulant medication, assess the symptoms promptly and arrange appropriate medical or cardiovascular evaluation before considering restarting treatment.
D. Reassure the patient that palpitations are always harmless if their previous blood pressure readings were normal.
Correct answer: C. Withhold stimulant medication, assess the symptoms promptly and arrange appropriate medical or cardiovascular evaluation before considering restarting treatment.
Explanation:
New chest discomfort associated with palpitations requires prompt clinical assessment in a patient receiving stimulant medication.
Although such symptoms do not necessarily indicate serious cardiovascular disease, they should not be dismissed.
The clinician should assess the nature, severity and timing of symptoms, relevant medical history and the need for urgent investigation.
Where a potentially significant cardiovascular problem is suspected, stimulant medication should be withheld pending appropriate evaluation.
Active or severe chest pain, syncope or other concerning features may require emergency assessment rather than routine referral.
Why the other answers are incorrect:
A: Cardiovascular concerns can arise during established treatment, not only during titration.
B: Increasing stimulant medication without investigating cardiovascular symptoms would be inappropriate and potentially unsafe.
D: Previously normal observations do not exclude a newly developing cardiovascular problem.
Key learning point: New potentially significant cardiovascular symptoms require prompt assessment, even in patients who have previously tolerated stimulant medication well.
Question 9. Medication Adherence
A 23-year-old university student with ADHD has been prescribed modified-release methylphenidate.
They frequently forget to request repeat prescriptions and occasionally miss several days of treatment.
They explain that they struggle to organise appointments, remember deadlines and manage their daily routine.
What is the most appropriate initial approach?
A. Conclude that the patient is insufficiently motivated to continue treatment.
B. Explore executive functioning difficulties and practical barriers to adherence, and consider strategies to simplify medication management.
C. Stop prescribing because missed doses demonstrate that medication is unnecessary.
D. Automatically increase the dose to compensate for missed medication.
Correct answer: B. Explore executive functioning difficulties and practical barriers to adherence, and consider strategies to simplify medication management.
Explanation:
ADHD can directly affect the executive functioning skills required to manage medication.
Difficulties with planning, organisation, prospective memory and time management may interfere with prescription requests and consistent medication-taking.
A supportive approach involves identifying barriers and considering practical interventions such as reminder systems, predictable prescription arrangements and simplified medication regimens.
At the same time, clinicians should assess medication use carefully and remain alert to any concerns about misuse or diversion.
Why the other answers are incorrect:
A: Assuming poor motivation overlooks the possibility that adherence difficulties are related to ADHD symptoms.
C: Missed medication does not establish that treatment is unnecessary. The patient may experience substantial impairment during periods without medication.
D: Increasing the dose does not address inconsistent medication use and may introduce additional safety concerns.
Key learning point: Supporting medication adherence is part of effective ADHD treatment, particularly when executive functioning difficulties interfere with treatment management.
Question 10. The Comprehensive Long-term Review
A 38-year-old adult has been taking methylphenidate for five years.
They report continued improvements in concentration and occupational functioning. Their blood pressure, pulse and weight remain satisfactory, and they have no significant adverse effects.
They explain that they are happy with their current treatment and would prefer not to make any changes.
What is the most appropriate management plan?
A. Stop medication because five years is too long to remain on stimulant treatment.
B. Reduce the dose because all patients should attempt a medication reduction annually.
C. Continue the established medication if clinically appropriate, document the ongoing benefits and safety assessment, and arrange continued monitoring and review.
D. Change to a different ADHD medication to reduce the risk of long-term tolerance.
Correct answer: C. Continue the established medication if clinically appropriate, document the ongoing benefits and safety assessment, and arrange continued monitoring and review.
Explanation:
There is no general requirement to stop or change effective ADHD medication solely because it has been prescribed for several years.
Where medication continues to provide meaningful functional benefits, remains well tolerated and is supported by satisfactory clinical monitoring, continued treatment may be appropriate.
NICE recommends that the annual medication review should consider whether treatment remains necessary and whether dose reduction or stopping medication might be appropriate.
However, this does not mean that every patient must reduce their dose or undergo a medication break.
The patient's preferences should form part of shared decision-making.
The clinician should document the rationale for continued treatment and arrange appropriate ongoing monitoring.
Why the other answers are incorrect:
A: There is no universal five-year limit on stimulant treatment. Duration alone is not a reason for discontinuation.
B: Annual consideration of ongoing treatment need does not mean that dose reduction is mandatory.
D: Routine medication switching is not recommended solely to prevent possible tolerance in a patient whose treatment remains effective.
Key learning point: Continuing a stable, effective medication regimen is an appropriate active clinical decision when supported by regular review and monitoring.
Final Reflection
Long-term ADHD prescribing requires clinicians to balance treatment effectiveness, physical safety, functional outcomes and patient preferences.
The most important skill is not simply knowing when to continue medication, but recognising when the patient's circumstances require a more detailed assessment or a change in management.
Before completing a long-term medication review, consider the following questions:
Does the medication continue to provide meaningful improvement in the patient's everyday functioning?
Have adverse effects, physical health or mental health changed since the previous review?
Are monitoring requirements being met, and have any abnormal findings been addressed?
Does the patient understand their treatment and feel involved in decisions about continuing it?
Is there a clear and safe plan for ongoing prescribing, monitoring and specialist review?
The central principle of long-term ADHD management is that treatment should continue for as long as its benefits justify its risks and burdens, with regular reassessment to ensure that it remains appropriate for the individual.
